Authors: Zhen Ma, Ming Li, Rui Guo, Yu Tian, Yongbin Zheng, Bingxin Huang, Yi You, Qing Xu, Ming Cui, Li Shen, Feng Lan, Hang Yang, Rucong Liu, Tao Yang, Feng Wan, Qihua He, Xiao Huo, Youkun Bi, Yingying Zhang, Yunpeng Ling
Published: 2025-01-03
Source: Full article
Following myocardial infarction (MI), the accumulation of CD86-positive macrophages in the ischemic injury zone leads to secondary myocardial damage. Precise pharmacological intervention targeting this process remains challenging. This study engineered a nanotherapeutic delivery system with CD86-positive macrophage-specific targeting and ultrasound-responsive release capabilities. A folic acid (FA)–modified ultrasound-responsive gene/drug delivery system, assembled from DOTAP, DSPE-PEG2000-FA, cholesterol, and perfluorohexane (PFH)—termed FA-PNBs—was developed to codeliver small interfering RNA of STAT1 (siSTAT1) and the small-molecule nitro-oleic acid (OA-NO